214 related articles for article (PubMed ID: 26961240)
1. Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.
Bostick CD; Hickey KM; Wollenberg LA; Flora DR; Tracy TS; Gannett PM
Drug Metab Dispos; 2016 May; 44(5):741-9. PubMed ID: 26961240
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
Subramanian M; Low M; Locuson CW; Tracy TS
Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
[TBL] [Abstract][Full Text] [Related]
3. Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions.
Mishin V; Heck DE; Laskin DL; Laskin JD
Toxicol Sci; 2014 Oct; 141(2):344-52. PubMed ID: 25061110
[TBL] [Abstract][Full Text] [Related]
4. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
6. Dissociation Constants of Cytochrome P450 2C9/Cytochrome P450 Reductase Complexes in a Lipid Bilayer Membrane Depend on NADPH: A Single-Protein Tracking Study.
Barnaba C; Taylor E; Brozik JA
J Am Chem Soc; 2017 Dec; 139(49):17923-17934. PubMed ID: 29148818
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus.
Subramanian M; Tam H; Zheng H; Tracy TS
Drug Metab Dispos; 2010 Jun; 38(6):1003-9. PubMed ID: 20215413
[TBL] [Abstract][Full Text] [Related]
8. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes.
Albassam AA; Ahad A; Alsultan A; Al-Jenoobi FI
Saudi Pharm J; 2018 Jul; 26(5):673-677. PubMed ID: 29989011
[TBL] [Abstract][Full Text] [Related]
10. Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathways.
Ding S; Yao D; Deeni YY; Burchell B; Wolf CR; Friedberg T
Biochem J; 2001 Jun; 356(Pt 2):613-9. PubMed ID: 11368792
[TBL] [Abstract][Full Text] [Related]
11. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
Takenaka T; Kazuki K; Harada N; Kuze J; Chiba M; Iwao T; Matsunaga T; Abe S; Oshimura M; Kazuki Y
Drug Metab Pharmacokinet; 2017 Feb; 32(1):61-68. PubMed ID: 28139373
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase.
Szczesna-Skorupa E; Kemper B
Mol Pharmacol; 2011 Mar; 79(3):340-50. PubMed ID: 21081644
[TBL] [Abstract][Full Text] [Related]
13. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
14. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
[TBL] [Abstract][Full Text] [Related]
15. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
Manga N; Duffy JC; Rowe PH; Cronin MT
SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
[TBL] [Abstract][Full Text] [Related]
16. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba.
Liu KH; Kim MJ; Jeon BH; Shon JH; Cha IJ; Cho KH; Lee SS; Shin JG
J Clin Pharm Ther; 2006 Feb; 31(1):83-91. PubMed ID: 16476124
[TBL] [Abstract][Full Text] [Related]
19. Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase.
Lin HL; Kenaan C; Zhang H; Hollenberg PF
Chem Res Toxicol; 2012 Dec; 25(12):2642-53. PubMed ID: 23016756
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.
Gannett PM; Kabulski J; Perez FA; Liu Z; Lederman D; Locuson CW; Ayscue RR; Thomsen NM; Tracy TS
J Am Chem Soc; 2006 Jul; 128(26):8374-5. PubMed ID: 16802783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
